Oral contraceptives and neuroactive steroids

Pharmacology Biochemistry and Behavior

Volumn 84, Issue 4, 2006, Pages 628-634

  Rapkin, Andrea J ^a   Biggio, Giovanni ^b,c   Concas, Alessandra ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c CNR Institute of Neuroscience   (Italy)

Author keywords

GABAA receptors; Mood; Neuroactive steroids; Oral contraceptives; Rat brain; Women

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; ANXIOLYTIC AGENT; DROSPIRENONE; ETHINYLESTRADIOL; GESTAGEN; LEVONORGESTREL; NEUROSTEROID; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; STEROID;

ACNE; ANXIETY; ARTICLE; BRAIN; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; HIRSUTISM; HUMAN; HYPOPHYSIS GONAD SYSTEM; LIPID BLOOD LEVEL; METABOLIC DISORDER; MOOD DISORDER; NONHUMAN; ORAL CONTRACEPTION; PATHOPHYSIOLOGY; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; RAT STRAIN; SIDE EFFECT; WEIGHT GAIN; AFFECT; BIOSYNTHESIS; DRUG EFFECT; FEMALE; REVIEW;

RATTUS;

AFFECT; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; NEUROTRANSMITTER AGENTS; PREMENSTRUAL SYNDROME; STEROIDS;

EID: 34249105871     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2006.06.008     Document Type: Article

References (51)

1. Andréen L., Sundström-Poromaa I., Bixo M., Andersson A., Nyberg S., and Bäckström T. Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone. Psychoneuroendocrinology 30 (2005) 212-224
2. In: Biggio G., and Purdy R.H. (Eds). Neurosteroids and brain function (International review of Neurobiology) vol. 46 (2001), Academic Press, New York
3. Blode H., Wuttke W., Loock W., Roll G., and Heithecker R. A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. Eur J Contracept Reprod Health Care 5 (2000) 256-264
4. Brenner P.F., Mishell Jr. D.R., Stanczyk F.Z., and Goebelsmann U. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel. Am J Obstet Gynecol 129 (1977) 133-140
5. Carlstrom K., Karlsson R., and Von Schoultz B. Diurnal rhythm and effects of oral contraceptives on serum dehydroepiandrosterone sulfate (DHEAS) are related to alterations in serum albumin rather than to changes in adrenocortical steroid secretion. Scand J Clin Lab Invest 62 (2002) 361-368
6. Concas A., Mostallino M.C., Porcu P., Follesa P., Barbaccia M.L., Trabucchi M., et al. Role of brain allopregnanolone in the plasticity of γ-aminobutyric acid type A receptor in rat brain during pregnancy and after delivery. Proc Natl Acad Sci U S A 95 (1998) 13284-13289
7. Dubrovsky B.O. Steroids, neuroactive steroids and neurosteroids in psychopathology. Prog Neuro-psychopharmacol Biol Psychiatry 29 (2005) 169-192
8. A receptor subunit mRNA expression by hypothalamic magnocellular neurons in the adult rat. J Neurosci 16 (1996) 4872-4880
9. A receptor expression and function during progesterone treatment and withdrawal. Mol Pharmacol 57 (2000) 1262-1270
10. 2 subunit gene expression induced by long-term administration of oral contraceptives in rats. Neuropharmacology 42 (2002) 325-336
11. Fritschy J.M., and Brunig I. Formation and plasticity of GABAergic synapses: physiological mechanisms and pathophysiological implications. Pharmacol Ther 98 (2003) 299-323
12. Genazzani A.D., Luisi M., Malavasi B., Strucchi C., Luisi S., Casarosa E., et al. Pulsatile secretory characteristics of allopregnanolone, a neuroactive steroid, during the menstrual cycle and in amenorrheic subjects. Eur J Endocrinol 146 (2002) 347-356
13. Girdler S.S., Straneva P.A., Light K.C., Pedersen C.A., and Morrow A.L. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry 49 (2001) 788-797
14. Goldzieher J.W. Are low-dose oral contraceptives safer and better?. Am J Obstet Gynecol 171t (1994) 587-590
15. Graham C.A., and Sherwin B.B. The relationship between mood and sexuality in women using an oral contraceptive as treatment for premenstrual syndrome. Psychoneuroendocrinology 18 (1993) 273-281
16. Joffe H., Cohen L.S., and Harlow B.L. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol 189 (2003) 1523-1530
17. Kahn L.S., and Halbreich U. Oral contraceptives and mood. Expert Opin Pharmacother 2 (2001) 1367-1382
18. Khisti R.T., Chopde C.T., and Jain S.P. Antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice forced swim test. Pharmacol Biochem Behav 67 (2000) 137-143
19. Kuhl H., Weber W., Mehlis W., Sandow J., and Taubert H.D. Time- and dose-dependent alterations of basal and LH-RH-stimulated LH-release during treatment with various hormonal contraceptives. Contraception 30 (1984) 467-482
20. Kurshan N., and Epperson C.N. Oral contraceptives and mood in women with and without premenstrual dysphoria: a theoretical model. Arch Womens Ment Health 9 (2005) 1-14
21. B-receptors rapidly reduces pituitary LH release and GnRH gene expression in the preoptic/anterior hypothalamic area of ovariectomized rats. Neuroendocrinology 61 (1995) 655-662
22. Lobo R.A., and Stanczyk F.Z. New knowledge in the physiology of hormonal contraceptives. Am J Obstet Gynecol 170 (1994) 1499-1507
23. Lovick T.A., Griffiths J.L., Dunn S.M., and Martin I.L. Changes in GABA(A) receptor subunit expression in the midbrain during the oestrous cycle in Wistar rats. Neuroscience 131 (2005) 397-405
24. Maguire J.L., Stell B.M., Rafizadeh M., and Mody I. Ovarian cycle-linked changes in GABA(A) receptors mediating tonic inhibition alter seizure susceptibility and anxiety. Nat Neurosci 8 (2005) 797-804
25. Mishell Jr. D.R. Oral steroid contraceptives. In: Mishell Jr. D.R., and Davajan V. (Eds). Infertility, contraception and reproductive endocrinology. 2nd ed. (1986), Medical Economic Company Inc, California 593-622
26. Mishell Jr. D.R., Thorneycroft I.H., Nakamura R.M., Nagata Y., and Stone S.C. Serum estradiol in women ingesting combination oral contraceptive steroids. Am J Obstet Gynecol 114 (1972) 923-928
27. Mishell Jr. D.R., Kletzky O.A., Brenner P.F., Roy S., and Nicoloff J. The effect of contraceptive steroids on hypothalamic-pituitary function. Am J Obstet Gynecol 128 (1977) 60-74
28. Oinonen K.A., and Mazmanian D. To what extent do oral contraceptives influence mood and affect?. J Affect Disord 70 (2002) 229-240
29. Ottander U., Poromaa I.S., Bjurulf E., Skytt A., Backstrom T., and Olofsson J.I. Allopregnanolone and pregnanolone are produced by the human corpus luteum. Mol Cell Endocrinol 239 (2005) 37-44
30. Paoletti A.M., Lello S., Fratta S., Orrù M., Ranuzzi F., Sogliano C., et al. Psychological effect of the oral contraceptive formulation containing 3 mg of drospirenone plus 30 μg of ethinyl estradiol. Fertil Steril 81 (2004) 645-651
31. Pearlstein T.B., Bachmann G.A., Zacur H.A., and Yonkers K.A. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 72 (2005) 414-421
32. Pearson Murphy B.E., Steinberg S.I., Hu F.Y., and Allison C.M. Neuroactive ring A-reduced metabolites of progesterone in human plasma during pregnancy: elevated levels of 5 alpha-dihydroprogesterone in depressed patients during the latter half of pregnancy. J Clin Endocrinol Metab 86 (2001) 5981-5987
33. Picazo O., Fernandez-Guasti A., Lemus A.E., and Garcia G.A. A-ring reduced derivatives of two synthetic progestins induce anxiolytic effects in ovariectomized rats. Brain Res 796 (1998) 45-52
34. Pisu M.G., and Serra M. Neurosteroids and neuroactive drugs in mental disorders. Life Sci 74 (2004) 3181-3197
35. Rabe T., Kowald A., Ortmann J., and Rehberger-Schneider S. Inhibition of skin 5α-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol 14 (2000) 223-230
36. Rapkin A.J., Morgan M., Goldman L., Brann D.W., Simone D., and Mahesh V.B. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 90 (1997) 709-714
37. Rapkin A., Morgan M., Sogliano C., Biggio G., and Concas A. Decreased neuroactive steroids induced by combined oral contraceptive pills are not associated with mood changes. Fertil Steril 85 (2006) 1371-1378
38. Rasgon N., Serra M., Biggio G., Pisu M.G., Fairbanks L., Tanavoli S., et al. Neuroactive steroid-serotonergic interaction: responses to an intravenous L-tryptophan challenge in women with premenstrual syndrome. Eur J Endocrinol 145 (2001) 25-33
39. Rudolph U., and Mohler H. Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. Annu Rev Pharmacol Toxicol 44 (2004) 475-498
40. Sanders S.A., Graham C.A., Bass J.L., and Bancroft J. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception 64 (2001) 51-58
41. Sangthawan M., and Taneepanichskul S. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 μg on premenstrual symptoms. Contraception 71 (2005) 1-7
42. Simic B., Kniewald J., and Kniewald Z. Influence of ethynodiol diacetate on the formation of A-Homo-3-Oxa-5α-Pregnane-4,20-dione in female rats. Endocr Regul 32 (1998) 125-131
43. 4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature 392 (1998) 926-930
44. 4 subunit in association with increased anxiety. J Neurosci 18 (1998) 5275-5284
45. Spona J., Elstein M., Feichtinger W., Sullivan H., Lüdicke F., Müller U., et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 54 (1996) 71-77
46. Sulak P.J., Kuehl T.J., Ortiz M., and Shull B.L. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 186 (2002) 1142-1149
47. Telleria C.M., Carrizo D.G., and Deis R.P. Levonorgestrel inhibits luteinizing hormone-stimulated progesterone production in rat luteal cells. J Steroid Biochem Mol Biol 50 (1994) 161-166
48. van Heusden A.M., and Fauser B.C.J.M. Residual ovarian activity during oral steroid contraception. Hum Reprod Updat 8 (2002) 345-358
49. Yonkers K.A., Brown C., Pearlstein T.B., Foegh M., Sampson-Landers C., and Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 106 (2005) 492-501
50. Wang M., Seippel L., Purdy R.H., and Backstrom T. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5 alpha-pregnane-3,20-dione and 3 alpha-hydroxy-5 alpha-pregnan-20-one. J Clin Endocrinol Metab 81 (1996) 1076-1082
51. Zimmemberg B., and Farley M.J. Sex differences in anxiety behavior in rats: role of gonadal hormones. Physiol Behav 54 (1993) 1119-1124